Related Experiment Videos
Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia
D A Thomas1, J Cortes, S O'Brien
1Departments of Leukemia, Hematopathology, and Lymphoma, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Summary
The Hyper-CVAD chemotherapy regimen shows effectiveness in treating adult Burkitt's-type acute lymphoblastic leukemia (B-ALL). Identifying high-risk patients is crucial for improving outcomes in B-ALL treatment.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Background:
- Burkitt's-type acute lymphoblastic leukemia (B-ALL) is an aggressive form of leukemia.
- Effective front-line treatment strategies for adult B-ALL are critical for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of a front-line intensive multiagent chemotherapy regimen, Hyper-CVAD, in adult patients with B-ALL.
- To assess treatment response and overall survival rates in this patient population.
Main Methods:
- A total of 26 adult patients with newly diagnosed, untreated B-ALL received the Hyper-CVAD regimen.
- The regimen involved alternating cycles of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) with high-dose methotrexate and cytarabine.
- Prophylactic measures including granulocyte colony-stimulating factor, antibiotics, and central nervous system (CNS) prophylaxis were administered.
Main Results:
- A complete remission (CR) rate of 81% was achieved, with 70% of patients achieving CR within 4 weeks.
- The 3-year overall survival rate was 49%, and the 3-year continuous CR rate was 61%.
- Factors associated with poorer survival included older age (≥60 years), poor performance status, anemia, thrombocytopenia, peripheral blasts, and elevated lactate dehydrogenase. Survival rates varied significantly based on the number of adverse features.
Conclusions:
- The Hyper-CVAD regimen demonstrates effectiveness as a front-line treatment for adult B-ALL.
- Identifying patients at high risk for relapse and developing improved methods for detecting residual disease are essential for implementing risk-oriented treatment approaches.